BBOT · BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics reported its first quarter 2026 financial results, highlighting a net loss of $42.1 million compared to $22.1 million in the same period last year. The increased loss was driven by a significant rise in R&D expenses to $39.8 million (from $20.6 million) and G&A expenses to $6.4 million (from $2.5 million). The R&D increase reflects higher clinical trial and manufacturing costs for its three lead programs: BBO-8520, BBO-11818, and BBO-10203. G&A expenses rose due to the initiation of standalone operations following the de-SPAC transaction. The company ended the quarter with $388.9 million in cash, cash equivalents, and marketable securities, which management expects to fund operations into 2028. On the operational front, BBOT reported encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs, with updated clinical data expected in the second half of 2026. Notably, BBO-8520 showed a 65% ORR in KRAS G12C NSCLC, BBO-11818 demonstrated a partial response in pancreatic cancer, and BBO-10203 achieved full target engagement without hyperglycemia. Additionally, the company announced executive changes effective April 20, 2026, appointing Pedro J. Beltran as CEO and Idan Elmelech as COO, with Neil Kumar becoming Executive Chairman and former CEO Eli Wallace serving as Senior Adviser. Peter F. Lebowitz was also appointed to the Board in March 2026. These developments position BBOT for key milestones in the coming quarters.